Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICARES Medicus's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 97.71.
ICARES Medicus's Days Inventory for the
three
months ended in Dec. 2025 was 344.28.
ICARES Medicus's Days Payable for the
three
months ended in Dec. 2025 was 27.17.
Therefore, ICARES Medicus's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2025 was 414.82.
ICARES Medicus (ROCO:6612) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
ICARES Medicus Cash Conversion Cycle Related Terms
ICARES Medicus Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for ICARES Medicus's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6612 vs ISRG, BDX, MDLN: Cash Conversion Cycle Comparison
For the Medical Instruments & Supplies subindustry, ICARES Medicus's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICARES Medicus Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICARES Medicus's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where ICARES Medicus's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
ICARES Medicus's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICARES Medicus (ROCO:6612) has a Cash Conversion Cycle of 414.82 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on ICARES Medicus and its competitors.
Is ICARES Medicus' Cash Conversion Cycle too high?
ICARES Medicus' current Cash Conversion Cycle is 414.82. The Medical Devices & Instruments industry median Cash Conversion Cycle is 158.82. ICARES Medicus' value of 414.82 is 161.2% above this industry median. Overall, ICARES Medicus has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ICARES Medicus' Cash Conversion Cycle compare to ISRG and BDX?
ICARES Medicus' Cash Conversion Cycle of 414.82 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 158.82. ICARES Medicus' value of 414.82 is 161.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 158.82, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICARES Medicus's current Cash Conversion Cycle of 414.82 is 161.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on ICARES Medicus and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 158.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICARES Medicus's current Cash Conversion Cycle is 414.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICARES Medicus stock overvalued right now?
Based on GuruFocus' analysis, ICARES Medicus (ROCO:6612) is currently considered Possible Value Trap. The stock's GF Value™ is NT$190.22, compared to a current price of NT$70.20 — trading 63.1% below its estimated fair value. The current Cash Conversion Cycle is 414.82 and 161.2% above the Medical Devices & Instruments industry median of 158.82. ICARES Medicus' overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For ICARES Medicus (ROCO:6612), the current Cash Conversion Cycle is 414.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICARES Medicus (ROCO:6612) Overvalued in 2026?
Based on GuruFocus' analysis, ICARES Medicus stock appears to be undervalued.
The current stock price of NT$70.20 is trading 63.1% below its estimated GF Value™ of NT$190.22.
GuruFocus considers ICARES Medicus to be Possible Value Trap.
Key valuation signals for ROCO:6612:
Cash Conversion Cycle: 414.82
GF Value™: NT$190.22 vs. price of NT$70.20 (63.1% below fair value)
Industry Position: 161.2% above the Medical Devices & Instruments median
No single metric tells the full story. See the ROCO:6612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICARES Medicus Inc is engaged in providing high-grade nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices. In addition, it also designs, develops, manufactures, and sells intraocular lenses and nanomedical devices. The company's operating segments are Europe and America, which derive maximum revenue, China, and R.O.C. Geographically, it generates maximum revenue from the United States, followed by Taiwan, Spain, England, Japan, China, Germany, and other countries.
84GF Score
Get the complete analysis for ROCO:6612
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6612 has been successfully added to your 
